Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reversed isolated forearm technique with regional sugammadex reversal of rocuronium block
2013-002164-53Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Oct 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Sugammadex and rocuronium, sponsored by Medical University of Vienna. Primary endpoint: Mean dose of sugammadex required for regional reversal. Started Oct 2013; status: completed.
02
Drugs
Sugammadexrocuronium
Beyond the preview
Go deeper on 2013-002164-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002164-53.